24th November 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

World's first hemophilia B gene therapy worth whopping $3.5 M approved by US FDA

CSL Behring and uniQure’s launched the first ever hemophilia B gene therapy “Hemgenix” with a price tag of a whooping $3.5 Million (₹28 Crore) per dose. The drug is now designated as the most expensive drug in the world.

Takeda’s BLA granted priority review by US FDA for Dengue Vaccine Candidate

On Wednesday, Takeda announced that US FDA has accepted and granted priority review of the BLA (Biologics License Application) for TAK-003, the firm’s investigational dengue vaccine candidate.

India's Pharma exports hiked by 138% since 2013-14

India’s Union Health Minister Mansukh Mandaviya posted a tweet with an infographic on Wednesday showing that India’s pharma exports have grown 138 percent in AprilOctober 2022-23 as compared to AprilOctober 2013-14.

Aurobindo unit signs agreement with Evive Biotech to commercialize 'Ryzneuta'

Aurobindo pharma declared that its unit had inked a licensing pact with Evive Biotech to commercialize the drug Ryzneuta in the US market. The drug is under late-stage review by the US regulatory body for chemotherapyinduced neutropenia.

EC approves AbbVie’s 'Skyrizi' to treat moderate to severe active Crohn's disease

The EC (European Commission) approved AbbVie’s Skyrizi (risankizumab, 600 mg intravenous [IV] induction, and 360 mg subcutaneous [SC] maintenance therapy) as the first specific interleukin-23 inhibitor indicated for the treatment of adults with moderate to severe active Crohn’s disease.

Indian healthcare ready to leverage 5G to propel intelligent data management

Indian pharma sector is gazing at 5G as it has the potential to provide excellent bandwidth which can be used to allow faster real-time data transfer of AR (Augmented reality) and VR (Virtual reality) and utilizing IoT, AI and ML in Pharma and healthcare.

Novartis' and MMV's malaria medicine moves to Phase III trials

Pharma giant Novartis and MMV (Medicines for Malaria Venture) announced on Wednesday that their investigational drug ganaplacide/lumefantrine solid dispersion formulation (SDF) is ready to enter into phase III development.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.
Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?